Definitive Healthcare (DH) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $62.7 million, down 4% year-over-year but exceeded guidance; adjusted EBITDA was $20.6 million (33% margin), down 5% year-over-year, and net loss was $187.8 million due to a $228.2 million goodwill impairment.

• Adjusted net income rose to $15.4 million, with margin discipline and strong cash flow from operations of $19.4 million and unlevered free cash flow of $24.3 million.

• Renewal rates improved modestly year-over-year but remain below target, with churn still elevated, especially in life sciences and among smaller customers.

• Strategic focus is on simplifying the product portfolio into a unified platform, driving retention, upsell, and operational improvements; new product enhancements launched include Market Forecast and Monocle Conferences.

• Announced $100 million share repurchase authorization and CFO transition effective June 2025.

Financial highlights

• Q3 2024 revenue: $62.7 million, down 4% year-over-year; adjusted EBITDA: $20.6 million (33% margin), down 5%; adjusted net income: $15.4 million, up 6%; adjusted EPS: $0.10.

• Adjusted gross profit was $51.7 million (82% margin), down 8% year-over-year; adjusted operating income was $19.0 million (30% margin), down 7%.

• Unlevered free cash flow was $24.3 million in Q3 and $85.2 million TTM, up 58% year-over-year.

• Net loss for Q3 was $187.8 million, driven by a $228.2 million goodwill impairment.

• Cash, cash equivalents, and short-term investments totaled $305.4 million; total debt outstanding was $247.5 million.

Outlook and guidance

• Q4 2024 revenue expected at $60–$61 million, down 7–9% year-over-year; adjusted EBITDA expected at $16–$17 million (26–28% margin); full-year 2024 revenue guidance is $250.0–$251.0 million, with adjusted EBITDA $77.5–$78.5 million.

• Adjusted net income for Q4 projected at $10.5–$11.5 million; full-year at $53.0–$54.0 million; adjusted EPS for Q4 expected at $0.07, full-year at $0.34–$0.35.

• Full-year 2024 profit outlook modestly improved; sequential revenue growth targeted for H2 2025, but 2025 revenue expected to be lower than 2024 with margin contraction.

• Guidance reflects tightened revenue range, maintaining the high end of prior guidance, and expects continued expansion of full-year adjusted EBITDA margin.

• cRPO declined 4% year-over-year, indicating ongoing challenges for 2025 revenue growth.